This company has been marked as potentially delisted and may not be actively trading. Alterity Therapeutics (PRAN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock PRAN vs. PROC, OPTN, VIRI, VHAQ, PYRGF, ATNM, OSTX, AADI, NBRV, and EGRXShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Procaps Group (PROC), OptiNose (OPTN), Virios Therapeutics (VIRI), Viveon Health Acquisition (VHAQ), PyroGenesis Canada (PYRGF), Actinium Pharmaceuticals (ATNM), OS Therapies (OSTX), Aadi Bioscience (AADI), Nabriva Therapeutics (NBRV), and Eagle Pharmaceuticals (EGRX). Alterity Therapeutics vs. Its Competitors Procaps Group OptiNose Virios Therapeutics Viveon Health Acquisition PyroGenesis Canada Actinium Pharmaceuticals OS Therapies Aadi Bioscience Nabriva Therapeutics Eagle Pharmaceuticals Procaps Group (NASDAQ:PROC) and Alterity Therapeutics (NASDAQ:PRAN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment. Do insiders and institutionals hold more shares of PROC or PRAN? 3.6% of Alterity Therapeutics shares are owned by institutional investors. 19.9% of Procaps Group shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is PROC or PRAN more profitable? Company Net Margins Return on Equity Return on Assets Procaps GroupN/A N/A N/A Alterity Therapeutics N/A N/A N/A Does the media refer more to PROC or PRAN? In the previous week, Procaps Group's average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score. Company Overall Sentiment Procaps Group Neutral Alterity Therapeutics Neutral Which has more volatility and risk, PROC or PRAN? Procaps Group has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Which has stronger valuation & earnings, PROC or PRAN? Procaps Group has higher revenue and earnings than Alterity Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProcaps Group$409.92M0.26$42.54MN/AN/AAlterity Therapeutics$150K246.23-$6.40M-$0.70-5.93 SummaryAlterity Therapeutics beats Procaps Group on 4 of the 6 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAN vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.94M$790.73M$5.54B$9.05BDividend YieldN/A4.84%5.24%4.02%P/E Ratio-5.931.3527.4320.22Price / Sales246.23226.97416.87118.64Price / CashN/A23.4436.8958.07Price / Book2.966.298.035.67Net Income-$6.40M-$27.73M$3.18B$249.13M Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRANAlterity TherapeuticsN/A$4.15+2.6%N/A+128.7%$36.94M$150K-5.9314Gap DownPROCProcaps GroupN/A$0.95-40.3%N/A-62.0%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeOPTNOptiNose0.7456 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190VIRIVirios TherapeuticsN/A$4.76-2.9%$5.00+5.0%+1,899.2%$91.67MN/A-17.635VHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumePYRGFPyroGenesis Canada0.0904 of 5 stars$0.33-5.5%N/A-36.9%$60.86M$9.14M-5.4390High Trading VolumeATNMActinium Pharmaceuticals2.7424 of 5 stars$1.70+11.8%$4.00+135.3%N/A$53.03M$81K-1.2230OSTXOS Therapies2.6597 of 5 stars$1.72+1.2%$18.00+946.5%N/A$48.33MN/A-2.00N/ANews CoverageHigh Trading VolumeAADIAadi Bioscience0.6517 of 5 stars$1.95-6.7%$1.67-14.5%+42.1%$48.16M$25.07M-0.8640News CoverageNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070EGRXEagle PharmaceuticalsN/A$2.75-1.4%N/A-45.5%$35.71M$257.55M0.00100Gap Down Related Companies and Tools Related Companies Procaps Group Competitors OptiNose Competitors Virios Therapeutics Competitors Viveon Health Acquisition Competitors PyroGenesis Canada Competitors Actinium Pharmaceuticals Competitors OS Therapies Competitors Aadi Bioscience Competitors Nabriva Therapeutics Competitors Eagle Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
